Research progress of ERCC1 in non-small cell lung cancer based on the platinum drugs
10.3760/cma.j.issn.1673-422X.2014.12.010
- VernacularTitle:ERCC1在以铂类药物为基础的非小细胞肺癌化疗中的研究进展
- Author:
Zhibao LIU
;
Jinghua ZHANG
- Publication Type:Journal Article
- Keywords:
Cisplatin;
Carcinoma,Non-small cell lung;
Excision repair cross complementing group 1
- From:
Journal of International Oncology
2014;41(12):909-912
- CountryChina
- Language:Chinese
-
Abstract:
Excision repair cross complementing group 1 (ERCC1) gene is an enzyme of the speed limit of DNA repair protein in nucleotide excision repair (NER) pathways.Researches suggest that ERCC1 has been associated with cisplatin resistance in non-small cell lung cancer (NSCLC) patients.Thus,ERCC1 gene is a new target in malignant tumor gene therapy research,providing a new approach for the treatment of malignant,especially NSCLC.
